A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Amilomotide (Primary) ; CNP 520 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms Generation S1
  • Sponsors Amgen; Novartis
  • Most Recent Events

    • 06 Sep 2017 Planned End Date changed from 27 Aug 2023 to 6 May 2024.
    • 06 Sep 2017 Planned primary completion date changed from 27 Aug 2023 to 6 May 2024.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top